Implementing a Metabolism-Informed Approach for Smoking Cessation in an Alaska Tribal Health System: Study Protocol for a Single-Arm Implementation Pilot Trial

Overview

Journal Res Sq

Date 2024 Feb 12

PMID 38343834

Authors

Kelley Jansen

Brianna Tranby

Aliassa Shane

Todd Takeno

Kelly Chadwick

Pamela Sinicrope

Jennifer Shaw

Rachel Tyndale

Jeffrey Harris

Christi Patten

Jaedon Avey

Affiliations

Soon will be listed here.

Abstract

Background: Individualized treatment for commercial tobacco smoking cessation, such as through the utilization of the nicotine metabolite ratio (NMR), offers substantial clinical benefit. NMR is a metabolism-informed biomarker that can be used to guide medication selection. NMR testing is particularly promising for tobacco cessation efforts in populations with high rates of smoking, such as some Alaska Native and American Indian (AN/AI) communities. To date, no prior study has evaluated the implementation of NMR-guided tobacco cessation with AN/AI populations.

Methods: The present "QUIT" protocol is a two-phase study that will occur at Southcentral Foundation (SCF), an Alaska Native-owned health system, serving 70,000 AN/AI people, based in Anchorage, Alaska. In Phase one, qualitative interviews with customer-owners (patients), providers and administrators (n = 36) and a 10-participant beta-test will be used to refine a strategy to implement NMR testing in the health system. Phase two will involve a single-arm pilot trial (n = 50) and qualitative interviews throughout data collection (n = 48) to evaluate the implementation strategy and explore the real-world acceptability and feasibility of NMR testing to guide tobacco cessation with AN/AI populations.

Discussion: This study utilizes a community-based participatory approach to refine and implement a nicotine metabolism-informed smoking cessation program in a Tribal healthcare setting. The process and findings from this study will reflect the importance of customer-owner choice and honor the lived experience involved in quitting commercial tobacco. Pilot study data will inform the effect and sample sizes required for a future pragmatic trial of NMR-guided smoking cessation.

References

Pratt R, Pernat C, Kerandi L, Kmiecik A, Strobel-Ayres C, Joseph A . "It's a hard thing to manage when you're homeless": the impact of the social environment on smoking cessation for smokers experiencing homelessness. BMC Public Health. 2019; 19(1):635. PMC: 6534899. DOI: 10.1186/s12889-019-6987-7. View

Shahab L, Beard E, Brown J, West R . Prevalence of NRT use and associated nicotine intake in smokers, recent ex-smokers and longer-term ex-smokers. PLoS One. 2014; 9(11):e113045. PMC: 4236146. DOI: 10.1371/journal.pone.0113045. View

Masaki K, Tateno H, Nomura A, Muto T, Suzuki S, Satake K . A randomized controlled trial of a smoking cessation smartphone application with a carbon monoxide checker. NPJ Digit Med. 2020; 3:35. PMC: 7067789. DOI: 10.1038/s41746-020-0243-5. View

Shahab L, West R, McNeill A . A randomized, controlled trial of adding expired carbon monoxide feedback to brief stop smoking advice: evaluation of cognitive and behavioral effects. Health Psychol. 2011; 30(1):49-57. DOI: 10.1037/a0021821. View

Creamer M, Wang T, Babb S, Cullen K, Day H, Willis G . Tobacco Product Use and Cessation Indicators Among Adults - United States, 2018. MMWR Morb Mortal Wkly Rep. 2019; 68(45):1013-1019. PMC: 6855510. DOI: 10.15585/mmwr.mm6845a2. View

Damschroder L, Aron D, Keith R, Kirsh S, Alexander J, Lowery J . Fostering implementation of health services research findings into practice: a consolidated framework for advancing implementation science. Implement Sci. 2009; 4:50. PMC: 2736161. DOI: 10.1186/1748-5908-4-50. View

Dempsey D, Tutka P, Jacob 3rd P, Allen F, Schoedel K, Tyndale R . Nicotine metabolite ratio as an index of cytochrome P450 2A6 metabolic activity. Clin Pharmacol Ther. 2004; 76(1):64-72. DOI: 10.1016/j.clpt.2004.02.011. View

Siegel S, Lerman C, Flitter A, Schnoll R . The Use of the Nicotine Metabolite Ratio as a Biomarker to Personalize Smoking Cessation Treatment: Current Evidence and Future Directions. Cancer Prev Res (Phila). 2020; 13(3):261-272. PMC: 7080293. DOI: 10.1158/1940-6207.CAPR-19-0259. View

Hukkanen J, Jacob 3rd P, Benowitz N . Metabolism and disposition kinetics of nicotine. Pharmacol Rev. 2005; 57(1):79-115. DOI: 10.1124/pr.57.1.3. View

10.

Avey J, Hiratsuka V, Beans J, Trinidad S, Tyndale R, Robinson R . Perceptions of pharmacogenetic research to guide tobacco cessation by patients, providers and leaders in a tribal healthcare setting. Pharmacogenomics. 2016; 17(4):405-15. PMC: 5558512. DOI: 10.2217/pgs.15.177. View

11.

Avey J, Schaefer K, Noonan C, Trinidad S, Muller C, Claw K . Identification of Sociodemographic, Clinical, and Genetic Factors to Aid Alaska Native and American Indian People to Successfully Quit Smoking. Nicotine Tob Res. 2023; 26(1):79-86. PMC: 10734384. DOI: 10.1093/ntr/ntad133. View

12.

Baker T, Piper M, Stein J, Smith S, Bolt D, Fraser D . Effects of Nicotine Patch vs Varenicline vs Combination Nicotine Replacement Therapy on Smoking Cessation at 26 Weeks: A Randomized Clinical Trial. JAMA. 2016; 315(4):371-9. PMC: 4824537. DOI: 10.1001/jama.2015.19284. View

13.

Wells Q, Freiberg M, Greevy Jr R, Tyndale R, Kundu S, Duncan M . Nicotine Metabolism-informed Care for Smoking Cessation: A Pilot Precision RCT. Nicotine Tob Res. 2017; 20(12):1489-1496. PMC: 6236077. DOI: 10.1093/ntr/ntx235. View

14.

Lerman C, Schnoll R, Hawk Jr L, Cinciripini P, George T, Wileyto E . Use of the nicotine metabolite ratio as a genetically informed biomarker of response to nicotine patch or varenicline for smoking cessation: a randomised, double-blind placebo-controlled trial. Lancet Respir Med. 2015; 3(2):131-138. PMC: 4480925. DOI: 10.1016/S2213-2600(14)70294-2. View

15.

Glasgow R, Vogt T, Boles S . Evaluating the public health impact of health promotion interventions: the RE-AIM framework. Am J Public Health. 1999; 89(9):1322-7. PMC: 1508772. DOI: 10.2105/ajph.89.9.1322. View